80 FR 53274 - Ophthalmic Practice Rules (Eyeglass Rule)
FEDERAL TRADE COMMISSION Federal Register Volume 80, Issue 171 (September 3, 2015)
Federal Register Volume 80, Issue 171 (September 3, 2015)
| Page Range | 53274-53276 | |
| FR Document | 2015-21578 |
[Federal Register Volume 80, Number 171 (Thursday, September 3, 2015)] [Proposed Rules] [Pages 53274-53276] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-21578] ----------------------------------------------------------------------- FEDERAL TRADE COMMISSION 16 CFR Part 456 Ophthalmic Practice Rules (Eyeglass Rule) AGENCY: Federal Trade Commission (``FTC'' or ``Commission''). ACTION: Advance notice of proposed rulemaking; request for comment. ----------------------------------------------------------------------- SUMMARY: The Commission is requesting public comment on its Trade Regulation Rule entitled ``Ophthalmic Practice Rules (Eyeglass Rule),'' which requires eye care practitioners to release eyeglass prescriptions to their patients (``Eyeglass Rule''). The Commission is soliciting comments about the efficiency, costs, benefits, and regulatory impact of the Rule as part of its systematic review of all current Commission regulations and guides. All interested persons are hereby given notice of the opportunity to submit written data, views, and arguments concerning the Rule. DATES: Written comments must be received on or before October 26, 2015. ADDRESSES: Interested parties may file a comment at https://ftcpublic.commentworks.com/ftc/ophthalmicruleanprm online or on paper, by following the instructions in the Instructions for Submitting Comments part of the SUPPLEMENTARY INFORMATION section below. Write ``Eyeglass Rule, 16 CFR part 456, Project No. R511996'' on your comment, and file your comment online at https://ftcpublic.commentworks.com/ftc/ophthalmicruleanprm by following the instructions on the web-based form. If you prefer to file your comment on paper, write ``Eyeglass Rule, 16 CFR part 456, Project No. R51199'' on your comment and on the envelope and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex B), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex B), Washington, DC 20024. FOR FURTHER INFORMATION CONTACT: Alysa Bernstein, Attorney, (202) 326- 3289, or Bonnie McGregor, Federal Trade Investigator, (202) 326-2356, Division of Advertising Practices, [[Page 53275]] Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW., Washington, DC 20580. SUPPLEMENTARY INFORMATION: I. Background The Eyeglass Rule requires an optometrist or ophthalmologist to provide the patient with one copy of the patient's eyeglass prescription, at no extra cost, immediately after an eye examination is completed.\1\ It defines a prescription as ``the written specifications for lenses for eyeglasses which are derived from an eye examination, including all of the information specified by state law, if any, necessary to obtain lenses for eyeglasses.'' \2\ --------------------------------------------------------------------------- \1\ 16 CFR 456.2 (a) and (c). A provider may withhold a patient's prescription until the patient has paid for the eye examination, but only if the provider would have required immediate payment if the examination had revealed that no ophthalmic goods were needed. Section 456.2(a). \2\ 16 CFR 456.1(g). --------------------------------------------------------------------------- The Rule prohibits an optometrist or ophthalmologist from conditioning the availability of an eye examination on a requirement that the patient agree to purchase ophthalmic goods from the optometrist or ophthalmologist,\3\ or providing the patient with a notice waiving the liability or responsibility of the provider for the accuracy of the exam or the ophthalmic goods and services dispensed by another seller.\4\ --------------------------------------------------------------------------- \3\ 16 CFR 456.2(b). \4\ 16 CFR 456.2(d). --------------------------------------------------------------------------- The Commission first promulgated the Eyeglass Rule in 1978 based on a finding that many consumers were being deterred from comparison shopping for eyeglasses because eye care practitioners refused to release prescriptions, even upon a patient's request, or charged an additional fee for release of a prescription.\5\ --------------------------------------------------------------------------- \5\ Advertising of Ophthalmic Goods and Services, Statement of Basis and Purpose and Final Trade Regulation Rule, 43 FR 23992, 23998 (June 2, 1978). The Commission also found that some practitioners refused to conduct an examination unless the patient agreed in advance to purchase eyeglasses from the prescriber and that some practitioners conditioned the release of a prescription on the signing of a waiver of liability. Id. --------------------------------------------------------------------------- In 1985, the Commission published a Notice of Proposed Rulemaking (``NPR'') requesting comments on certain issues relating to the Rule, including whether or not the prescription release requirement should be modified to require that prescriptions be given only to patients who request them, modified to require only that eye care practitioners offer, rather than automatically provide, prescriptions to patients, and whether the Rule should be extended to require that optometrists and ophthalmologists provide a duplicate copy of prescriptions to patients who lost or misplaced the original.\6\ After considering the Rulemaking record, the Commission decided in 1989 to retain the Rule's requirement that prescriptions be automatically released.\7\ The Commission did not receive substantial evidence indicating that the practice of refusing to release duplicate copies of eyeglass prescriptions to patients who had lost or misplaced the originals was prevalent and as a result determined that rulemaking in that area would not be appropriate.\8\ --------------------------------------------------------------------------- \6\ Ophthalmic Practice Rules; Proposed Trade Regulation Rule; Notice of Proposed Rulemaking, 50 FR 598, 602 (Jan. 4, 1985). \7\ Trade Regulation Rule; Ophthalmic Practice Rules; Final Trade Regulation Rule, 54 FR 10285, 10303 (Mar. 13, 1989). Citing to significant non-compliance with the automatic release requirement of the Rule and a lack of consumer awareness about prescription rights, the Commission determined that there was not sufficient evidence in the record to conclude that the automatic release provision was no longer needed. Id. \8\ 54 FR 10285, 10303 (Mar. 13, 1989). --------------------------------------------------------------------------- In 1997, the Commission issued a Request for Public Comment regarding the Rule, inviting comments on the overall costs and benefits of the Rule, and asking again if the automatic prescription release requirement should be modified.\9\ In 2004, following comments from numerous parties, the Commission determined to retain the Eyeglass Rule without modification.\10\ --------------------------------------------------------------------------- \9\ Ophthalmic Practice Rules; Request for Public Comments, 62 FR 15865 (Apr. 3, 1997). \10\ Ophthalmic Practice Rules; Final Rule; 69 FR 5451 (Feb. 4, 2004). --------------------------------------------------------------------------- II. Regulatory Review of the Eyeglass Rule The Commission periodically reviews all of its rules and guides. These reviews seek information about the costs and benefits of the agency's rules and guides, and their regulatory and economic impact. The information obtained assists the Commission in identifying those rules and guides that warrant modification or rescission. Therefore, the Commission solicits comments on, among other things, the economic impact and benefits of the Rule; possible conflict between the Rule and State, local, or other Federal laws or regulations; and the effect on the Rule of any technological, economic, or other industry changes. III. Issues for Comment The Commission requests written comment on any or all of the following questions. These questions are designed to assist the public and should not be construed as a limitation on the issues on which public comment may be submitted. The Commission requests that responses to its questions be as specific as possible, including a reference to the question being answered, and reference to empirical data or other evidence upon which comments are based whenever available and appropriate. Please also provide evidence of the prevalence of any unfair acts or practices that any proposed modification would address. A. General Issues 1. Is there a continuing need for the Rule? Why or why not? 2. What benefits has the Rule provided to consumers? What evidence supports the asserted benefits? 3. What modifications, if any, should be made to the Rule to increase its benefits to consumers? (a) What evidence supports the proposed modifications? (b) How would these modifications affect the costs the Rule imposes on businesses, including small businesses? (c) How would these modifications affect the benefits to consumers? 4. What impact has the Rule had on the flow of truthful information to consumers and on the flow of deceptive information to consumers? 5. What significant costs, if any, has the Rule imposed on consumers? What evidence supports the asserted costs? 6. What modifications, if any, should be made to the Rule to reduce any costs imposed on consumers? (a) What evidence supports the proposed modifications? (b) How would these modifications affect the benefits provided by the Rule? 7. What benefits, if any, has the Rule provided to businesses, including small businesses? What evidence supports the asserted benefits? 8. What modifications, if any, should be made to the Rule to increase its benefits to businesses, including small businesses? (a) What evidence supports the proposed modifications? (b) How would these modifications affect the costs the Rule imposes on businesses, including small businesses? (c) How would these modifications affect the benefits to consumers? 9. What significant costs, if any, including costs of compliance, has the Rule imposed on businesses, including small businesses? What evidence supports the asserted costs? 10. What modifications, if any, should be made to the Rule to reduce the costs imposed on businesses, including small businesses? (a) What evidence supports the proposed modifications? (b) How would these modifications affect the benefits provided by the Rule? [[Page 53276]] 11. What evidence is available concerning the degree of industry compliance with the Rule? 12. What modifications, if any, should be made to the Rule to account for changes in relevant technology or economic conditions? What evidence supports the proposed modifications? 13. Does the Rule overlap or conflict with other federal, state, or local laws or regulations? If so, how? (a) What evidence supports the asserted conflicts? (b) With reference to the asserted conflicts, should the Rule be modified? If so, why, and how? If not, why not? B. Specific Issues 1. Should the definition of ``prescription'' be modified to include pupillary distance? Why or why not? (a) What evidence supports such a modification? (b) How would this modification affect the costs the Rule imposes on businesses, including small businesses? (c) How would this modification affect the benefits to consumers? 2. Should the Rule be extended to require that prescribers provide a duplicate copy of a prescription to a patient who does not currently have access to the original? Why or why not? (a) What evidence supports such a modification? (b) How would this modification affect the costs the Rule imposes on businesses, including small businesses? (c) How would this modification affect the benefits to consumers? 3. Should the Rule be extended to require that a prescriber provide a copy to or verify a prescription with third parties authorized by the patient? Why or why not? (a) What evidence supports such a modification? (b) How would this modification affect the costs the Rule imposes on businesses, including small businesses? (c) How would this modification affect the benefits to consumers? IV. Instructions for Submitting Comments You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before October 26, 2015. Write ``Eyeglass Rule, 16 CFR part 456, Project No. R511996'' on the comment. Your comment, including your name and your state, will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at http://www.ftc.gov/os/publiccomments.shtm. As a matter of discretion, the Commission tries to remove individuals' home contact information from comments before placing them on the Commission Web site. Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, such as a Social Security number, date of birth, driver's license number or other state identification number or foreign country equivalent, passport number, financial account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, do not include any ``[t]rade secret or any commercial or financial information which is . . . privileged or confidential,'' as discussed in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names. If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you must follow the procedure explained in FTC Rule 4.9(c), 16 CFR 4.9(c). In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comments to be withheld from the public record. Your comment will be kept confidential only if the FTC General Counsel, in his sole discretion, grants your request in accordance with the law and the public interest. Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comment online. To make sure that the Commission considers your online comment, you must file it at https://ftcpublic.commentworks.com/ftc/ophthalmicruleanprm by following the instructions on the web-based form. If this document appears at http://www.regulations.gov/#!home, you also may file a comment through that Web site. If you file your comment on paper, write ``Eyeglass Rule, 16 CFR part 456, Project No. R511996'' on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex B), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex B), Washington, DC 20024. Visit the Commission Web site at http://www.ftc.gov to read this document and the news release describing it. The FTC Act and other laws that the Commission administers permit the collection of public comments to consider and use in this proceeding as appropriate. The Commission will consider all timely and responsive public comments that it receives on or before October 26, 2015. You can find more information, including routine uses permitted by the Privacy Act, in the Commission's privacy policy, at http://www.ftc.gov/ftc/privacy.htm. By direction of the Commission. Donald S. Clark, Secretary. [FR Doc. 2015-21578 Filed 9-2-15; 8:45 am] BILLING CODE 6750-01-P
![53274 Federal Register / Vol. 80, No. 171 / Thursday, September 3, 2015 / Proposed Rules
10. What modifications, if any, should manufacturing processes, or customer By direction of the Commission.
be made to the Rule to reduce the costs names. Donald S. Clark
imposed on businesses, including small If you want the Commission to give Secretary.
businesses? your comment confidential treatment, [FR Doc. 2015–21577 Filed 9–2–15; 8:45 am]
a. What evidence supports the
you must file it in paper form, with a BILLING CODE 6750–01–P
proposed modifications?
b. How would these modifications request for confidential treatment, and
affect the benefits provided by the Rule? you must follow the procedure
FEDERAL TRADE COMMISSION
11. What evidence is available explained in FTC Rule 4.9(c), 16 CFR
concerning the degree of industry 4.9(c). In particular, the written request 16 CFR Part 456
compliance with the Rule? for confidential treatment that
12. What modifications, if any, should accompanies the comment must include Ophthalmic Practice Rules (Eyeglass
be made to the Rule to account for the factual and legal basis for the Rule)
changes in relevant technology or request, and must identify the specific AGENCY: Federal Trade Commission
economic conditions? What evidence portions of the comments to be withheld (‘‘FTC’’ or ‘‘Commission’’).
supports the proposed modifications? from the public record. Your comment
13. Does the Rule overlap or conflict ACTION: Advance notice of proposed
will be kept confidential only if the FTC rulemaking; request for comment.
with other federal, state, or local laws or General Counsel, in his or her sole
regulations? If so, how? discretion, grants your request in SUMMARY: The Commission is requesting
a. What evidence supports the public comment on its Trade Regulation
accordance with the law and the public
asserted conflicts? Rule entitled ‘‘Ophthalmic Practice
b. With reference to the asserted interest.
Rules (Eyeglass Rule),’’ which requires
conflicts, should the Rule be modified? Postal mail addressed to the
eye care practitioners to release eyeglass
If so, why, and how? If not, why not? Commission is subject to delay due to
prescriptions to their patients (‘‘Eyeglass
heightened security screening. As a Rule’’). The Commission is soliciting
IV. Instructions for Submitting
result, we encourage you to submit your comments about the efficiency, costs,
Comments
comment online. To make sure that the benefits, and regulatory impact of the
You can file a comment online or on Commission considers your online
paper. For the Commission to consider Rule as part of its systematic review of
comment, you must file it at https:// all current Commission regulations and
your comment, we must receive it on or ftcpublic.commentworks.com/ftc/
before October 26, 2015. Write ‘‘Contact guides. All interested persons are
contactlensrule by following the hereby given notice of the opportunity
Lens Rule, 16 CFR part 315, Project No. instructions on the web-based form. If
R511995’’ on the comment. Your to submit written data, views, and
this document appears at http:// arguments concerning the Rule.
comment, including your name and
www.regulations.gov/#!home, you also DATES: Written comments must be
your state, will be placed on the public
record of this proceeding, including, to may file a comment through that Web received on or before October 26, 2015.
the extent practicable, on the public site. ADDRESSES: Interested parties may file a
Commission Web site, at http:// If you file your comment on paper, comment at https://
www.ftc.gov/os/publiccomments.shtm. write ‘‘Contact Lens Rule, 16 CFR part ftcpublic.commentworks.com/ftc/
As a matter of discretion, the 315, Project No. R511995’’ on your ophthalmicruleanprm online or on
Commission tries to remove individuals’ comment and on the envelope, and mail paper, by following the instructions in
home contact information from your comment to the following address: the Instructions for Submitting
comments before placing them on the Federal Trade Commission, Office of the Comments part of the SUPPLEMENTARY
Commission Web site. Because your Secretary, 600 Pennsylvania Avenue INFORMATION section below. Write
comment will be made public, you are NW., Suite CC–5610 (Annex C), ‘‘Eyeglass Rule, 16 CFR part 456, Project
solely responsible for making sure that Washington, DC 20580, or deliver your No. R511996’’ on your comment, and
your comment does not include any file your comment online at https://
comment to the following address:
sensitive personal information, such as ftcpublic.commentworks.com/ftc/
Federal Trade Commission, Office of the
a Social Security number, date of birth, ophthalmicruleanprm by following the
Secretary, Constitution Center, 400 7th instructions on the web-based form. If
driver’s license number or other state Street SW., 5th Floor, Suite 5610
identification number or foreign country you prefer to file your comment on
(Annex C), Washington, DC 20024. paper, write ‘‘Eyeglass Rule, 16 CFR part
equivalent, passport number, financial
account number, or credit or debit card Visit the Commission Web site at 456, Project No. R51199’’ on your
number. You are also solely responsible http://www.ftc.gov to read this comment and on the envelope and mail
for making sure that your comment does document and the news release your comment to the following address:
not include any sensitive health describing it. The FTC Act and other Federal Trade Commission, Office of the
information, such as medical records or laws that the Commission administers Secretary, 600 Pennsylvania Avenue
other individually identifiable health permit the collection of public NW., Suite CC–5610 (Annex B),
information. comments to consider and use in this Washington, DC 20580, or deliver your
In addition, do not include any proceeding as appropriate. The comment to the following address:
‘‘[t]rade secret or any commercial or Commission will consider all timely Federal Trade Commission, Office of the
rmajette on DSK7SPTVN1PROD with PROPOSALS
financial information which is . . . and responsive public comments that it Secretary, Constitution Center, 400 7th
privileged or confidential,’’ as discussed receives on or before October 26, 2015. Street SW., 5th Floor, Suite 5610
in Section 6(f) of the FTC Act, 15 U.S.C. You can find more information, (Annex B), Washington, DC 20024.
46(f), and FTC Rule 4.10(a)(2), 16 CFR including routine uses permitted by the FOR FURTHER INFORMATION CONTACT:
4.10(a)(2). In particular, do not include Privacy Act, in the Commission’s Alysa Bernstein, Attorney, (202) 326–
competitively sensitive information privacy policy, at http://www.ftc.gov/ 3289, or Bonnie McGregor, Federal
such as costs, sales statistics, ftc/privacy.htm. Trade Investigator, (202) 326–2356,
inventories, formulas, patterns, devices, Division of Advertising Practices,
VerDate Sep<11>2014 13:54 Sep 02, 2015 Jkt 235001 PO 00000 Frm 00010 Fmt 4702 Sfmt 4702 E:\FR\FM\03SEP1.SGM 03SEP1](https://thefederalregister.org/doc/80_FR_53445/page/1.svg)
![53276 Federal Register / Vol. 80, No. 171 / Thursday, September 3, 2015 / Proposed Rules
11. What evidence is available your comment, we must receive it on or will be kept confidential only if the FTC
concerning the degree of industry before October 26, 2015. Write General Counsel, in his sole discretion,
compliance with the Rule? ‘‘Eyeglass Rule, 16 CFR part 456, Project grants your request in accordance with
12. What modifications, if any, should No. R511996’’ on the comment. Your the law and the public interest.
be made to the Rule to account for comment, including your name and Postal mail addressed to the
changes in relevant technology or your state, will be placed on the public Commission is subject to delay due to
economic conditions? What evidence record of this proceeding, including, to heightened security screening. As a
supports the proposed modifications? the extent practicable, on the public
13. Does the Rule overlap or conflict result, we encourage you to submit your
Commission Web site, at http:// comment online. To make sure that the
with other federal, state, or local laws or www.ftc.gov/os/publiccomments.shtm.
regulations? If so, how? Commission considers your online
As a matter of discretion, the comment, you must file it at https://
(a) What evidence supports the Commission tries to remove individuals’
asserted conflicts? ftcpublic.commentworks.com/ftc/
home contact information from ophthalmicruleanprm by following the
(b) With reference to the asserted comments before placing them on the
conflicts, should the Rule be modified? instructions on the web-based form. If
Commission Web site. Because your this document appears at http://
If so, why, and how? If not, why not? comment will be made public, you are
www.regulations.gov/#!home, you also
B. Specific Issues solely responsible for making sure that
may file a comment through that Web
1. Should the definition of your comment does not include any
site.
‘‘prescription’’ be modified to include sensitive personal information, such as
a Social Security number, date of birth, If you file your comment on paper,
pupillary distance? Why or why not? write ‘‘Eyeglass Rule, 16 CFR part 456,
(a) What evidence supports such a driver’s license number or other state
identification number or foreign country Project No. R511996’’ on your comment
modification?
(b) How would this modification equivalent, passport number, financial and on the envelope, and mail your
affect the costs the Rule imposes on account number, or credit or debit card comment to the following address:
businesses, including small businesses? number. You are also solely responsible Federal Trade Commission, Office of the
(c) How would this modification for making sure that your comment does Secretary, 600 Pennsylvania Avenue
affect the benefits to consumers? not include any sensitive health NW., Suite CC–5610 (Annex B),
2. Should the Rule be extended to information, such as medical records or Washington, DC 20580, or deliver your
require that prescribers provide a other individually identifiable health comment to the following address:
duplicate copy of a prescription to a information. Federal Trade Commission, Office of the
patient who does not currently have In addition, do not include any Secretary, Constitution Center, 400 7th
access to the original? Why or why not? ‘‘[t]rade secret or any commercial or Street SW., 5th Floor, Suite 5610
(a) What evidence supports such a financial information which is . . . (Annex B), Washington, DC 20024.
modification? privileged or confidential,’’ as discussed Visit the Commission Web site at
(b) How would this modification in Section 6(f) of the FTC Act, 15 U.S.C. http://www.ftc.gov to read this
affect the costs the Rule imposes on 46(f), and FTC Rule 4.10(a)(2), 16 CFR document and the news release
businesses, including small businesses? 4.10(a)(2). In particular, do not include describing it. The FTC Act and other
(c) How would this modification competitively sensitive information laws that the Commission administers
affect the benefits to consumers? such as costs, sales statistics, permit the collection of public
3. Should the Rule be extended to
inventories, formulas, patterns, devices, comments to consider and use in this
require that a prescriber provide a copy
manufacturing processes, or customer proceeding as appropriate. The
to or verify a prescription with third
names. Commission will consider all timely
parties authorized by the patient? Why
If you want the Commission to give and responsive public comments that it
or why not?
(a) What evidence supports such a your comment confidential treatment, receives on or before October 26, 2015.
modification? you must file it in paper form, with a You can find more information,
(b) How would this modification request for confidential treatment, and including routine uses permitted by the
affect the costs the Rule imposes on you must follow the procedure Privacy Act, in the Commission’s
businesses, including small businesses? explained in FTC Rule 4.9(c), 16 CFR privacy policy, at http://www.ftc.gov/
(c) How would this modification 4.9(c). In particular, the written request ftc/privacy.htm.
affect the benefits to consumers? for confidential treatment that By direction of the Commission.
accompanies the comment must include
IV. Instructions for Submitting Donald S. Clark,
the factual and legal basis for the
Comments request, and must identify the specific Secretary.
You can file a comment online or on portions of the comments to be withheld [FR Doc. 2015–21578 Filed 9–2–15; 8:45 am]
paper. For the Commission to consider from the public record. Your comment BILLING CODE 6750–01–P
rmajette on DSK7SPTVN1PROD with PROPOSALS
VerDate Sep<11>2014 13:54 Sep 02, 2015 Jkt 235001 PO 00000 Frm 00012 Fmt 4702 Sfmt 9990 E:\FR\FM\03SEP1.SGM 03SEP1](https://thefederalregister.org/doc/80_FR_53445/page/3.svg)
Document Created: 2015-12-15 09:56:56
Document Modified: 2015-12-15 09:56:56
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Proposed Rules | |
| Action | Advance notice of proposed rulemaking; request for comment. | |
| Dates | Written comments must be received on or before October 26, 2015. | |
| Contact | Alysa Bernstein, Attorney, (202) 326- 3289, or Bonnie McGregor, Federal Trade Investigator, (202) 326-2356, Division of Advertising Practices, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW., Washington, DC 20580. | |
| FR Citation | 80 FR 53274 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR